The origins of the story to decipher the mechanisms that control the growth of sex hormone–
dependent cancers started more than 100 years ago. Clinical observations of the apparently …

Background Estrogens suppress tumor growth in prostate cancer which progresses despite
anorchid serum androgen levels, termed castration resistant prostate cancers (CRPC) …

Several therapeutic strategies are actually available in the management of prostate cancer:
Targeting the androgen receptor (AR) is the goal both for initial androgen deprivation …

Management of metastatic or advanced prostate cancer has acquired several therapeutic
approaches that have drastically changed the course of the disease. In particular due to the …

Ablation of the androgen-signaling axis is currently a dominant theme in developmental
therapeutics in prostate cancer. Highly potent inhibitors of androgen biosynthesis and …

Prostate cancer (PC) is the most prevalent type of cancer in men worldwide. In Saudi Arabia,
the rate of PC is increasing annually. The sex steroid hormones androgens and their …

The prostate is an androgen-dependent organ that develops only in male mammals.
Prostate cancer is the most common nonskin malignancy in men and the second leading …

It has been appreciated for more than 60 years that prostate cancer cells are responsive to
androgen deprivation therapy (ADT). In 1941, Huggins and Hodges [1] observed the …

Surgical ovariectomy and orchiectomy, first proposed over a century ago, are effective in
breast and prostate cancer therapy, respectively. Later, the discovery of steroid hormones …

Prostate cancer and breast cancer are sex-steroid–dependent diseases that are driven in
major part by gonadal sex steroids. Testosterone (T) is converted to 5α-dihydrotestosterone …